新生児毒性の市場規模、シェア、動向分析レポート：検体別、薬剤別、技術別、最終用途別、地域別、セグメント予測、2024年～2030年

新生児毒性市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の新生児毒性の市場規模は、2024年から2030年までの予測CAGRが10.6%で、2030年までに5億1,405万米ドルに達する見込みです。

母親の薬物使用による新生児禁忌症候群（NAS）などの新生児障害の有病率の上昇が、新生児毒物検査と治療の需要を牽引しています。さらに、質量分析計のような先進的な診断技術の開発は、新生児の毒物曝露の検出と管理を改善し、それによって市場の成長を促進しています。

この憂慮すべき動向は、効果的な新生児毒性ソリューションの緊急ニーズを強調しています。過去数十年の間に、薬物スクリーニング・ツールは大きく進歩し、現在では以前よりも正確で精密な結果が得られるようになった。従来、薬物検査は酵素結合免疫吸着測定法（ELISA）を用いて行われてきました。この方法にはいくつかの利点があります。比較的安価で、一般的な検査室で簡単に実施でき、納期が早いことです。さらに、ELISAが長年使用されてきた結果、様々なヒト組織での使用が検証された複数の市販抗体が利用できるようになった。尿中のコカイン代謝物の検出のような特定の検査では、ELISAは信頼できる方法です。しかし、他の薬物と組織の組み合わせでは、偽陽性と陰性の両方の発生率が比較的高いです。

さらに、マサチューセッツ州最大のヘルスケア・システムであるマス・ジェネラル・ブリガムは、2024年4月、赤ちゃんが薬物に暴露されて生まれた場合、虐待やネグレクトの疑いがある場合の報告方法を大幅に変更することを発表しました。この方針転換は、イェール・ニューヘイブン小児病院やボストン・メディカル・センターなどのシステムでも採用されており、妊娠中の薬物使用に対して、より思いやりのある、エビデンスに基づいた対応を目指す、より広範な傾向を示しています。これらの医療機関では、出生時に薬物に暴露されたすべての事例を報告するのではなく、乳児が身体的または精神的な傷害を受ける危険性があると信じるに足る合理的な理由がある場合にのみ報告することにしています。このアプローチは、懲罰的措置が親子双方にとってより悪い医療結果につながり、有色人種や社会経済的地位の低い家庭には不釣り合いな影響を与えるというコンセンサスの高まりを反映しています。この進化する政策情勢は、新生児毒物検査業界にとって重大な意味を持っています。懲罰的なアプローチから、より支持的でリハビリテーション的な手段へのシフトは、新生児毒物検査の需要と利用における変化を促進すると予想されます。

コネチカット州、ニューメキシコ州、ワシントン州、コロラド州などでは州法が改正され、マサチューセッツ州では薬物使用障害で処方された薬を服用している母親を保護するための法案が提出中であるため、毒物検査の実施基準はより洗練されたものになる可能性があります。これにより、より的を絞った検査が行われるようになり、資源が効率的に使われ、本当に必要な場合にのみ検査が行われるようになるかもしれないです。さらに、市場が支持療法にシフトするにつれて、包括的で低侵襲なスクリーニング・ソリューションを提供する新技術の成長の可能性が大きくなっています。これには、高分解能質量分析や革新的なバイオマーカーのような技術の進歩が含まれ、大規模な侵襲的処置を行うことなく、新生児の曝露や健康状態についてより詳細な洞察を得ることができます。

新生児毒性市場レポート・ハイライト

• 検体に基づくと、2023年に最大の収益シェアを占めたのはメコニウムでした。糞便検体は、妊娠後期の薬物曝露を検出することで、新生児毒性において重要な利点を提供し、より長い検出ウィンドウを提供します。
• 質量分析は、新生児毒性におけるゴールドスタンダードであり、ナノグラムレベルの薬物曝露を検出するための比類のない感度と特異性を提供します。その利点には、高い精度、低い検出限界、初期スクリーニングからの陽性結果を確認する能力が含まれます。
• 薬物に基づくと、2023年にはカンナビノイド・セグメンテーションが最大の市場シェアで市場を独占しました。妊娠中のカンナビノイド使用は増加しており、妊婦の2～5％が使用を自己申告しており、都市部の低所得女性では28％という高率です。この増加の背景には、合法化、安全性の認識、吐き気への使用があります。
• 最終用途別では、臨床検査部門が2023年に最大の売上シェアを占めました。Arup LaboratoriesとQuest Diagnosticsは、出生前の薬物曝露を検出するための包括的な検査サービスを提供する市場の主要プレーヤーです。
• 北米は、多数の主要な市場プレイヤーの存在、新生児薬物曝露の高い有病率、出生前薬物乱用の悪影響に対する意識の高まりにより、市場を独占しています。
• アジア太平洋地域は、2024年から2030年までの予測期間で最も速いCAGRを示すことが期待されています。ヘルスケアインフラの拡大と妊娠中の薬物乱用を減らすことを目的とした公衆衛生イニシアチブの実施により、この地域での市場成長が期待されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 新生児毒性市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• 新生児毒性市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 新生児毒性市場：検体別推定・動向分析

• 検体別市場シェア、2023年および2030年
• セグメントダッシュボード
• 検体別世界新生児毒性市場展望
• 2018年から2030年までの市場規模と予測および動向分析

第5章 新生児毒性市場：技術別推定・動向分析

• 技術別市場シェア、2023年と2030年
• セグメントダッシュボード
• 技術展望による世界の新生児毒性市場
• 2018年から2030年までの市場規模と予測および動向分析

第6章 新生児毒性市場：薬剤タイプ別推定・動向分析

• 薬剤タイプ別市場シェア、2023年および2030年
• セグメントダッシュボード
• 薬剤タイプ別世界新生児毒性市場展望
• 2018年から2030年までの市場規模と予測および動向分析

第7章 新生児毒性市場：エンドユーザー別推定・動向分析

• エンドユーザー別市場シェア、2023年および2030年
• セグメントダッシュボード
• エンドユーザー別世界新生児毒性市場展望
• 2018年から2030年までの市場規模と予測および動向分析

第8章 新生児毒性市場：地域別推定・動向分析

• 地域別市場シェア分析、2023年および2030年
• 地域別市場ダッシュボード
• 世界の地域市場スナップショット
• 市場規模と予測動向分析、2018年から2030年：
• 北米
  • 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店およびチャネル パートナーのリスト
  • 主要顧客
  • 主要企業の市場シェア分析、2023 年
  • Quest Diagnostics Incorporated
  • USDTL
  • Quidel Corporation
  • Thermo Fisher Scientific, Inc.
  • Omega Laboratories, Inc.
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Laboratory Corporation of America Holdings
  • Clinical Reference Laboratory, Inc.
  • Cordant Health Solutions

List of Tables

• Table 1 List of abbreviations
• Table 2 North America neonatal toxicology market, by region, 2018 - 2030 (USD Million)
• Table 3 North America neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 4 North America neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 5 North America neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 6 North America neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 7 U.S. neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 8 U.S. neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 9 U.S. neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 10 U.S. neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 11 Canada neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 12 Canada neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 13 Canada neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 14 Canada neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 15 Mexico neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 16 Mexico neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 17 Mexico neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 18 Mexico neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 19 Europe neonatal toxicology market, by region, 2018 - 2030 (USD Million)
• Table 20 Europe neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 21 Europe neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 22 Europe neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 23 Europe neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 24 Germany neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 25 Germany neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 26 Germany neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 27 Germany neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 28 UK neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 29 UK neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 30 UK neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 31 UK neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 32 France neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 33 France neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 34 France neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 35 France neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 36 Italy neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 37 Italy neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 38 Italy neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 39 Italy neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 40 Spain neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 41 Spain neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 42 Spain neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 43 Spain neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 44 Denmark neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 45 Denmark neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 46 Denmark neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 47 Denmark neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 48 Sweden neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 49 Sweden neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 50 Sweden neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 51 Sweden neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 52 Norway neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 53 Norway neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 54 Norway neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 55 Norway neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 56 Asia Pacific neonatal toxicology market, by region, 2018 - 2030 (USD Million)
• Table 57 Asia Pacific neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 58 Asia Pacific neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 59 Asia Pacific neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 60 Asia Pacific neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 61 China neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 62 China neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 63 China neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 64 China neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 65 Japan neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 66 Japan neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 67 Japan neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 68 Japan neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 69 India neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 70 India neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 71 India neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 72 India neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 73 South Korea neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 74 South Korea neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 75 South Korea neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 76 South Korea neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 77 Australia neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 78 Australia neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 79 Australia neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 80 Australia neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 81 Thailand neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 82 Thailand neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 83 Thailand neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 84 Thailand neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 85 Latin America neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 86 Latin America neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 87 Latin America neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 88 Latin America neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 89 Brazil neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 90 Brazil neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 91 Brazil neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 92 Brazil neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 93 Argentina neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 94 Argentina neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 95 Argentina neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 96 Argentina neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 97 MEA neonatal toxicology market, by region, 2018 - 2030 (USD Million)
• Table 98 MEA neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 99 MEA neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 100 MEA neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 101 MEA neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 102 South Africa neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 103 South Africa neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 104 South Africa neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 105 South Africa neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 106 Saudi Arabia neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 107 Saudi Arabia neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 108 Saudi Arabia neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 109 Saudi Arabia neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 110 UAE neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 111 UAE neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 112 UAE neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 113 UAE neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
• Table 114 Kuwait neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
• Table 115 Kuwait neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
• Table 116 Kuwait neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
• Table 117 Kuwait neonatal toxicology market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Neonatal toxicology market: market outlook
• Fig. 14 Neonatal toxicology competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Penetration and growth prospect mapping
• Fig. 18 Industry value chain analysis
• Fig. 19 Neonatal toxicology market driver impact
• Fig. 20 Neonatal toxicology market restraint impact
• Fig. 21 Neonatal toxicology market strategic initiatives analysis
• Fig. 22 Neonatal toxicology market: Specimen movement analysis
• Fig. 23 Neonatal toxicology market: Specimen outlook and key takeaways
• Fig. 24 Urine market estimates and forecast, 2018 - 2030
• Fig. 25 Umbilical cord estimates and forecast, 2018 - 2030
• Fig. 26 Meconium market estimates and forecast, 2018 - 2030
• Fig. 27 Others market estimates and forecast, 2018 - 2030
• Fig. 28 Neonatal toxicology Market: Technology movement analysis
• Fig. 29 Neonatal toxicology market: Technology outlook and key takeaways
• Fig. 30 Mass spectroscopy market estimates and forecasts, 2018 - 2030
• Fig. 31 Immunoassay market estimates and forecasts,2018 - 2030
• Fig. 32 Neonatal toxicology market: Drug movement analysis
• Fig. 33 Neonatal toxicology market: Drug outlook and key takeaways
• Fig. 34 Cannabinoids market estimates and forecast, 2018 - 2030
• Fig. 35 Opioids estimates and forecast, 2018 - 2030
• Fig. 36 Amphetamines market estimates and forecast, 2018 - 2030
• Fig. 37 Cocaine market estimates and forecast, 2018 - 2030
• Fig. 38 Benzodiazepines market estimates and forecast, 2018 - 2030
• Fig. 39 Others illicit drugs market estimates and forecast, 2018 - 2030
• Fig. 40 Neonatal toxicology market: End use movement analysis
• Fig. 41 Neonatal toxicology market: End use outlook and key takeaways
• Fig. 42 Hospitals market estimates and forecasts, 2018 - 2030
• Fig. 43 Clinical Laboratories market estimates and forecasts,2018 - 2030
• Fig. 44 Others market estimates and forecasts, 2018 - 2030
• Fig. 45 Global neonatal toxicology market: Regional movement analysis
• Fig. 46 Global neonatal toxicology market: Regional outlook and key takeaways
• Fig. 47 Global neonatal toxicology market share and leading players
• Fig. 48 North America market share and leading players
• Fig. 49 Europe market share and leading players
• Fig. 50 Asia Pacific market share and leading players
• Fig. 51 Latin America market share and leading players
• Fig. 52 Middle East & Africa market share and leading players
• Fig. 53 North America, by country
• Fig. 54 North America
• Fig. 55 North America market estimates and forecasts, 2018 - 2030
• Fig. 56 U.S. key country dynamics
• Fig. 57 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 58 Canada key country dynamics
• Fig. 59 Canada market estimates and forecasts, 2018 - 2030
• Fig. 60 Mexico key country dynamics
• Fig. 61 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 62 Europe
• Fig. 63 Europe market estimates and forecasts, 2018 - 2030
• Fig. 64 UK key country dynamics
• Fig. 65 UK market estimates and forecasts, 2018 - 2030
• Fig. 66 Germany key country dynamics
• Fig. 67 Germany market estimates and forecasts, 2018 - 2030
• Fig. 68 France key country dynamics
• Fig. 69 France market estimates and forecasts, 2018 - 2030
• Fig. 70 Italy key country dynamics
• Fig. 71 Italy market estimates and forecasts, 2018 - 2030
• Fig. 72 Spain key country dynamics
• Fig. 73 Spain market estimates and forecasts, 2018 - 2030
• Fig. 74 Denmark key country dynamics
• Fig. 75 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 76 Sweden key country dynamics
• Fig. 77 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 78 Norway key country dynamics
• Fig. 79 Norway market estimates and forecasts, 2018 - 2030
• Fig. 80 Asia Pacific
• Fig. 81 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 82 China key country dynamics
• Fig. 83 China market estimates and forecasts, 2018 - 2030
• Fig. 84 Japan key country dynamics
• Fig. 85 Japan market estimates and forecasts, 2018 - 2030
• Fig. 86 India key country dynamics
• Fig. 87 India market estimates and forecasts, 2018 - 2030
• Fig. 88 Thailand key country dynamics
• Fig. 89 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 90 South Korea key country dynamics
• Fig. 91 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 92 Australia key country dynamics
• Fig. 93 Australia market estimates and forecasts, 2018 - 2030
• Fig. 94 Latin America
• Fig. 95 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 96 Brazil key country dynamics
• Fig. 97 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 98 Argentina key country dynamics
• Fig. 99 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 100 Middle East and Africa
• Fig. 101 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 102 South Africa key country dynamics
• Fig. 103 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 104 Saudi Arabia key country dynamics
• Fig. 105 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 106 UAE key country dynamics
• Fig. 107 UAE market estimates and forecasts, 2018 - 2030
• Fig. 108 Kuwait key country dynamics
• Fig. 109 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 110 Market share of key market players - Neonatal toxicology market

Neonatal Toxicology Market Growth & Trends:

The global neonatal toxicology market size is expected to reach USD 514.05 million by 2030, at a projected CAGR of 10.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of neonatal disorders, such as neonatal abstinence syndrome (NAS) due to maternal drug use, drives the demand for neonatal toxicology testing and treatments. In addition, the development of advanced diagnostic technologies, such as mass spectrometers, improves the detection and management of toxic exposures in neonates, thereby propelling market growth.

This alarming trend underscores the urgent need for effective neonatal toxicology solutions. Over the past several decades, there have been significant advancements in drug screening tools, which now provide more accurate and precise results than ever before. Traditionally, drug testing has been performed using enzyme-linked immunosorbent assays (ELISAs). This method has several advantages: it is relatively inexpensive, easy to perform in a general laboratory, and has a rapid turnaround time. Moreover, the long-standing use of ELISA has resulted in the availability of multiple commercial antibodies validated for use in various human tissues. For certain tests, such as detecting cocaine metabolites in urine, ELISA is a reliable method. However, for other drug and tissue combinations, there is a relatively high incidence of both false positives and negatives.

In addition, Mass General Brigham, Massachusetts' largest healthcare system, in April 2024 announced a significant shift in its approach to reporting suspected abuse or neglect in cases where a baby is born exposed to drugs. This policy change, now adopted by systems like Yale New Haven Children's Hospital and Boston Medical Center, signifies a broader trend toward more compassionate and evidence-based responses to substance use during pregnancy. Rather than reporting every instance of drug exposure at birth, these health systems will only report if there is reasonable cause to believe the infant is at risk of physical or emotional injury. This approach reflects a growing consensus that punitive measures lead to worse medical outcomes for both parent and child and disproportionately impact families of color and those with low socioeconomic status. This evolving policy landscape has profound implications for the neonatal toxicology testing industry. The shift away from punitive approaches towards more supportive and rehabilitative measures is expected to drive changes in the demand and utilization of neonatal toxicology tests.

With revised state laws in places like Connecticut, New Mexico, Washington, and Colorado and pending legislation in Massachusetts to protect mothers on prescribed medications for substance use disorder, the criteria for conducting toxicology tests may become more refined. This could lead to more targeted testing, ensuring that resources are used efficiently and that testing is conducted only when truly necessary. In addition, as the market shifts towards supportive care, there is significant potential for growth in emerging technologies that offer comprehensive and minimally invasive screening solutions. This includes advancements in technologies like high-resolution mass spectrometry and innovative biomarkers that can provide more detailed insights into neonatal exposure and health without extensive invasive procedures.

Neonatal Toxicology Market Report Highlights:

• Based on the specimen, meconium accounted for the largest revenue share in 2023. Meconium specimens offer a key advantage in neonatal toxicology by detecting drug exposure over the last trimester of pregnancy, providing a longer detection window.
• Based on technology, mass spectroscopy dominated the market in 2023.Mass spectrometry is the gold standard in neonatal toxicology, offering unparalleled sensitivity and specificity for detecting drug exposure at nanogram levels. Its advantages include high accuracy, low detection limits, and the ability to confirm positive results from initial screenings.
• Based on the drug, the cannabinoids segment dominated the market in 2023 with the largest market share. Cannabinoid use during pregnancy is rising, with 2-5% of pregnant women self-reporting use and rates as high as 28% among low-income urban women. This increase is driven by legalization, perceived safety, and use for nausea.
• Based on end use, the clinical laboratories segment dominated the market with the largest revenue share in 2023. Arup Laboratories and Quest Diagnostics are key players in the market, providing comprehensive testing services to detect prenatal drug exposure.
• North America dominated the market due to the presence of a large number of major market players, the high prevalence of neonatal drug exposure, and the increasing awareness of the adverse effects of prenatal drug abuse.
• The Asia Pacific region is expected to witness the fastest CAGR over the forecast period from 2024 to 2030. Due to the expansion of healthcare infrastructure and the implementation of public health initiatives aimed at reducing drug abuse during pregnancy, market growth is expected in this region.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Specimen
  • 1.2.2. Technology
  • 1.2.3. Drug
  • 1.2.4. End User
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Specimen outlook
  • 2.2.2. Technology outlook
  • 2.2.3. Drug outlook
  • 2.2.4. End User outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Neonatal Toxicology Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. High prevalence of substance abuse
    • 3.2.1.2. Stringent laws mandating alcohol and drug testing
    • 3.2.1.3. Increasing government initiatives to monitor substance abuse
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Neonatal toxicology is considered a violation of privacy rights in some countries
• 3.3. Neonatal Toxicology Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Neonatal Toxicology Market: Specimen Estimates & Trend Analysis

• 4.1. Specimen Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Neonatal Toxicology Market by Specimen Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Urine
    • 4.4.1.1. Urine market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Umbilical Cord
    • 4.4.2.1. Umbilical cord market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Meconium
    • 4.4.3.1. Meconium market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Others
    • 4.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Neonatal Toxicology Market: Technology Estimates & Trend Analysis

• 5.1. Technology Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Neonatal Toxicology Market by Technology Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Mass spectroscopy
    • 5.4.1.1. Mass spectroscopy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Immunoassay
    • 5.4.2.1. Immunoassay market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Neonatal Toxicology Market: Drug type Estimates & Trend Analysis

• 6.1. Drug type Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Neonatal Toxicology Market by Drug type Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Cannabinoids
    • 6.4.1.1. Cannabinoids Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Opioids
    • 6.4.2.1. Opioids Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Cocaine
    • 6.4.3.1. Cocaine Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Benzodiazepines
    • 6.4.4.1. Benzodiazepines market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Amphetamines
    • 6.4.5.1. Amphetamines Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Other illicit drugs
    • 6.4.6.1. Other illicit drugs Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Neonatal Toxicology Market: End User Estimates & Trend Analysis

• 7.1. End User Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Neonatal Toxicology Market by End User Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Hospitals
    • 7.4.1.1. Hospitals Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Clinical Laboratories
    • 7.4.2.1. Clinical Laboratories Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Others
    • 7.4.3.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Neonatal Toxicology Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2023 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 8.5. North America
  • 8.5.1. North America
  • 8.5.2. U.S.
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. Canada
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Mexico
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Europe
  • 8.6.1. Europe
  • 8.6.2. UK
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ Reimbursement
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. Germany
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ Reimbursement
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. France
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ Reimbursement
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Italy
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ Reimbursement
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Spain
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Norway
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.8. Sweden
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.9. Denmark
    • 8.6.9.1. Key country dynamics
    • 8.6.9.2. Regulatory framework/ Reimbursement
    • 8.6.9.3. Competitive scenario
    • 8.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Asia Pacific
  • 8.7.2. Japan
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ Reimbursement
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. China
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ Reimbursement
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. India
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ Reimbursement
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.5. Australia
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ Reimbursement
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.6. South Korea
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/ Reimbursement
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.7. Thailand
    • 8.7.7.1. Key country dynamics
    • 8.7.7.2. Regulatory framework/ Reimbursement
    • 8.7.7.3. Competitive scenario
    • 8.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. Latin America
  • 8.8.1. Latin America
  • 8.8.2. Brazil
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. Argentina
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework/ Reimbursement
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.9. MEA
  • 8.9.1. MEA
  • 8.9.2. South Africa
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework/ Reimbursement
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.3. Saudi Arabia
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework/ Reimbursement
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.4. UAE
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework/ Reimbursement
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.5. Kuwait
    • 8.9.5.1. Key country dynamics
    • 8.9.5.2. Regulatory framework
    • 8.9.5.3. Competitive scenario
    • 8.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2023
  • 9.3.4. Quest Diagnostics Incorporated
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Others benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. USDTL
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Others benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Quidel Corporation
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Others benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Thermo Fisher Scientific, Inc.
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Others benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Omega Laboratories, Inc.
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Others benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Bio-Rad Laboratories, Inc.
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Others benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Agilent Technologies, Inc.
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Others benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Laboratory Corporation of America Holdings
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Others benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. Clinical Reference Laboratory, Inc.
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Others benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Cordant Health Solutions
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Others benchmarking
    • 9.3.13.4. Strategic initiatives